Showing results (941-950 of 1,182) with videos related to
Sort By:
Pageof 119
Applied Health Economics and Health Policy|July 25, 2018
Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in ItalyMatteo Ruggeri, Federica Romano, Michele Basile, et al.Applied Health Economics and Health Policy|October 19, 2019
Implicitly Estimating the Cost of Mental Illness in Australia: A Standard-of-Living ApproachSon Nghiem, Rasheda Khanam, Xuan-Binh Vu, et al.Applied Health Economics and Health Policy|April 26, 2022
Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in BurundiFulgence Niyibitegeka, Montarat Thavorncharoensap, Arthorn Riewpaiboon, et al.Applied Health Economics and Health Policy|June 5, 2019
Developing Attributes and Attribute-Levels for a Discrete-Choice Experiment: An Example for Interventions of Impulsive Violent OffendersStella Nalukwago Settumba, Marian Shanahan, Tony Butler, et al.Applied Health Economics and Health Policy|June 29, 2019
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian AdultsAshleigh McGirr, Desiree Van Oorschot, Robyn Widenmaier, et al.Applied Health Economics and Health Policy|January 27, 2022
Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among AdolescentsMimmi Åström, Ola Rolfson, Kristina BurströmApplied Health Economics and Health Policy|October 5, 2018
Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert SystemIrene Eriksson, Mia von Euler, Rickard E Malmström, et al.Applied Health Economics and Health Policy|April 23, 2010
Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in GermanyThilo M Schaufler, Malte WolffApplied Health Economics and Health Policy|June 30, 2009
Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extractionAlan G White, Howard G Birnbaum, Dov B Rothman, et al.Applied Health Economics and Health Policy|April 23, 2009
A pharmacoeconomic analysis of compliance gains on antipsychotic medicationsJoep Damen, Per-Olof Thuresson, Bart Heeg, et al.Pageof 119